Monoclonal antilymphocyte antibody (OKT3) treatment of acute renal allograft rejection.
Recent advances in immunosuppressive therapy have dramatically improved the survival rates for recipients of organ allografts by reducing the frequency of rejection. Cyclosporine, azathioprine, and prednisone for immunoprophylaxis are especially effective. When rejection occurs, the treatment usually includes high doses of oral or intravenous corticosteroids, antilymphocyte globulin, or antithymocyte globulin. A new monoclonal antilymphocyte antibody, OKT3, promises to improve allograft survival rates further.
Canafax
D M
DM
Department of Pharmacy Practice, College of Pharmacy, University of Minnesota, Minneapolis 55455.
Draxler
C A
CA
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D006084:Graft Rejection; D006801:Humans; D016030:Kidney Transplantation
D000911:Antibodies, Monoclonal